Market Research Reports and Industry Reports

Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • PURCHASE BY
    SECTION
All biotech companies - Gilead (GILD), Amgen (AMGN), Biogen Idec (BIIB) and Celgene (CELG), in past year, have given a positive return and hence increased the interest of biotech investors. These companies have been able to select therapy/niche indication where the high treatment cost justifies the need. While large pharma companies are active in M&A deals, the Mature biotech companies are sticking to its core expertise and venturing into unexplored/new therapy; e.g., GILD in anti-cancer and BIIB for hemophilia. Alike small molecule generics, biosimilar will also get easier and getting similar pace of recognition in coming years; where AMGN, BIIB already started investing in this space and can emerge as a big player in coming years.

REGN, ALXN, and VRTX have transformed into a large-cap mature biotech companies. Whether these three will be acquired or will remain independent and evolve in next giant is still a question, but both the cases present a good investment opportunity for those who willing to hold them for next five years.

GILD has announced the dividend payment and now all eyes will be on CELG and BIIB
~Amgen : Table 1 : COMPETITIVE LANDSCAPE: ANTI-PCSK9 MAB ALIROCUMAB VS. EVLOCUMAB
~Biogen Idec : Annexure 1 : MULTIPLE SCLEROSIS INJECTABLE DRUGS DATA COMPARISON
~Celgene : Table 1: Hematological Malignancies Multiple Myeloma (MM)
DATA COMPARISON NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)
Table 2 : Hematological Malignancies Multiple Myeloma (MM) DATA COMPARISON RELAPSED / REFRACTORY MULTIPLE MYELOMA (RRMM)
~Gilead : Table 1 : Development Pipeline
Key Pipeline Product :
Table 2: KEY PIPELINE PRODUCTS: IFN-FREE COMBINATION
~Regeneron : Tale 1: BRANCH RETINAL VEIN OCCLUSION (BRVO): CLINICAL DATA ANALYSIS
Table 2A: CLINICAL DATA: ANTI-PCSK9 MAB, ALIROCUMAB AT AMERICAN HEART ASSOCIATION 2014
Table 2B: COMPETITIVE LANDSCAPE: ANTI-PCSK9 MAB ALIROCUMAB VS. EVOLOCUMAB
~Vertex : Table 1: PHIIB DATA OF IVACAFTOR IN RESIDUAL CFTR FUNCTION
Table 2 : PHIIB DATA OF IVACAFTOR IN RESIDUAL CFTR FUNCTION
Table 3: PHIII PRIMARY EFFICACY DATA FROM IVACAFTOR/ LUMACAFTOR
COMBINATION
Table 4 :PHIII SECONDARY EFFICACY DATA FROM IVACAFTOR/ LUMACAFTOR
COMBINATION
Table 5 : PHIII POOLED PRIMARY EFFICACY DATA FROM
IVACAFTOR/ LUMACAFTOR COMBINATION
Table 6: PHIII POOLED SECONDARY EFFICACY DATA FROM
IVACAFTOR/ LUMACAFTOR COMBINATION

List Of Tables

~Gilead Sciences: Figure 1: MACROGENICS: DART TECHNOLOGY
~Regeneron : Figure 1 : SAR236553/REGN727: PHASE III CLINICAL PROGRAM
~Vertex: Figure 1 : MUTATIONS AND DRUGS TARGET

List Of Figures

~Amgen : Table 1 : COMPETITIVE LANDSCAPE: ANTI-PCSK9 MAB ALIROCUMAB VS. EVLOCUMAB
~Biogen Idec : Annexure 1 : MULTIPLE SCLEROSIS INJECTABLE DRUGS DATA COMPARISON
~Celgene : Table 1: Hematological Malignancies Multiple Myeloma (MM)
DATA COMPARISON NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)
Table 2 : Hematological Malignancies Multiple Myeloma (MM) DATA COMPARISON RELAPSED / REFRACTORY MULTIPLE MYELOMA (RRMM)
~Gilead : Table 1 : Development Pipeline
Key Pipeline Product :
Table 2: KEY PIPELINE PRODUCTS: IFN-FREE COMBINATION
~Regeneron : Tale 1: BRANCH RETINAL VEIN OCCLUSION (BRVO): CLINICAL DATA ANALYSIS
Table 2A: CLINICAL DATA: ANTI-PCSK9 MAB, ALIROCUMAB AT AMERICAN HEART ASSOCIATION 2014
Table 2B: COMPETITIVE LANDSCAPE: ANTI-PCSK9 MAB ALIROCUMAB VS. EVOLOCUMAB
~Vertex : Table 1: PHIIB DATA OF IVACAFTOR IN RESIDUAL CFTR FUNCTION
Table 2 : PHIIB DATA OF IVACAFTOR IN RESIDUAL CFTR FUNCTION
Table 3: PHIII PRIMARY EFFICACY DATA FROM IVACAFTOR/ LUMACAFTOR
COMBINATION
Table 4 :PHIII SECONDARY EFFICACY DATA FROM IVACAFTOR/ LUMACAFTOR
COMBINATION
Table 5 : PHIII POOLED PRIMARY EFFICACY DATA FROM
IVACAFTOR/ LUMACAFTOR COMBINATION
Table 6: PHIII POOLED SECONDARY EFFICACY DATA FROM
IVACAFTOR/ LUMACAFTOR COMBINATION

EMEA (Europe, Middle East and Africa) Balanced-armature Magnetic Speakers Market Report 2017

In this report, the EMEA Balanced-armature Magnetic Speakers market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022,

USD 4000View Report

Global Balanced-armature Magnetic Speakers Sales Market Report 2017

In this report, the global Balanced-armature Magnetic Speakers market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022,

USD 4000View Report

Premature Ejaculation - Pipeline Review, H1 2017

Premature Ejaculation - Pipeline Review, H1 2017Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Premature Ejaculation - Pipeline Review, H1 2017, provides an overview of the Premature Ejaculation

USD 2000View Report

Global Biotech Flavor Market Professional Survey Report 2017

This report studies Biotech Flavor in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from

USD 3500View Report

PharmaCyte Biotech Inc (PMCB) - Financial and Strategic SWOT Analysis Review

PharmaCyte Biotech Inc (PharmaCyte), formerly Nuvilex, Inc. is a clinical stage biotechnology company that develops and commercializes treatments for cancer and diabetes. The company develops Cell-in-a-Box cellulose-based live cell encapsulation

USD 300View Report

Mycenax Biotech Inc (4726) - Financial and Strategic SWOT Analysis Review

Mycenax Biotech Inc (Mycenax) develops and manufactures pharmaceutical formulations. The companys pipeline portfolio encompasses investigational candidates targeted at the treatment of plaque psoriasis, glioblastoma, asthma, adult crohns Disease, and breast

USD 300View Report

Fill The Form For Sample Request
Name*
Email*
Mobile No.*
LandLine No.
Country Code.
If you want to purchase particular section from this report then kindly contact us at contact@aarkstore.com.

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    $ 2000
  • Site Licence    $ 4000
  • Enterprisewide Licence    $ 6000
$ 2000

Reports Details

Published Date : Jan 2015
No. of Pages :90
Country :Global
Category :Healthcare
Publisher :MP Advisors
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment
  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube